Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Amicus Therapeutics
Biotech
After phase 3 fumble, Amicus' Pompe disease drug hits new delay
The company’s late-phase Pompe disease drug has faced another setback in the form a delayed FDA review.
James Waldron
May 11, 2022 10:20am
Amicus' SPAC merger folds, triggering search for $400M in cuts
Feb 24, 2022 8:10am
Amicus axes gene therapy program for type of Batten disease
Jan 10, 2022 3:20pm
FDA's vaccine office now headed by Marks—Chutes & Ladders
Oct 1, 2021 9:30am
Amicus spins off gene therapy unit in $600M SPAC deal
Sep 29, 2021 8:35am
Amicus misses goal in Pompe phase 3 but pushes for approval
Feb 12, 2021 7:30am
